Clinical Trial Detail

NCT ID NCT02014337
Title Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Corcept Therapeutics
Indications

ureter transitional cell carcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

peritoneum cancer

urethra transitional cell carcinoma

breast cancer

fallopian tube cancer

sarcoma

prostate cancer

ovarian cancer

lung non-small cell carcinoma

triple-receptor negative breast cancer

Therapies

Eribulin + Mifepristone

Age Groups:

No variant requirements are available.